There’s a reason the world’s most patient investors love dividend stocks.
Market movements heavily influence a stock’s capital-gains potential in a given year. But dividends are usually paid whether the broader market is up or down, and that dependability is a big reason to factor them in when buying stock.
“Dividends can provide not only income, but they may also accelerate the payback on investment,” Fidelity says.
That logic plays out perfectly with Eli Lilly.
A decade ago, Eli Lilly (LLY) was already a solid pharmaceutical company. But investors who bought early and held on didn’t just enjoy a massive stock price run-up.
They quietly unlocked something even more rewarding, a yield-on-cost that has ballooned to 9%. That’s the kind of return that makes dividend stock investing click for a lot of people.
Here’s how it happened.
$1,000 in LLY stock became a 9% income machine
In 2016, Eli Lilly shares traded at roughly $77, and a $1,000 investment would have bought you about 13 shares.
At the time, the annual dividend was $2.04 per share. Those 13 shares would have generated $26.52 in annual dividend income, a yield of about 2.6% on your original investment. Nothing flashy, but solid.
Fast-forward to today.
Eli Lilly now pays $1.73 per share quarterly, or an annual dividend of $6.92 per share. Those same 13 shares you bought in 2016 now throw off roughly $90 in annual dividend income.
Related: Eli Lilly’s pill solves the biggest problem with weight loss
That’s a yield-on-cost of 9%.
Your original investment didn’t change. The number of shares didn’t change. But because Lilly kept raising its payout year after year, the income you collect on that initial $1,000 keeps growing.
This is the compounding magic that makes dividend stocks so powerful for long-term investors.
Here’s a snapshot of LLY’s key dividend metrics:
- Annual dividend per share: $6.92
- Quarterly dividend per share: $1.73
- Current dividend yield: About 0.7%
- 5-year dividend growth rate: Approximately 15.2% annually
- Consecutive years of dividend increases: 12
- Dividend growth since 2014: About 11% annually
Since 2014, Eli Lilly has increased its dividend at an annual rate of 11%, and given an annual dividend expense of $6.2 billion, the company has plenty of room to keep raising its payout.
In 2025, LLY reported free cash flow of $8.9 billion, indicating a payout ratio of almost 77%. However, FCF is projected to balloon to almost $47 billion by 2030.
If Eli Lilly stock maintains a payout ratio of just 30%, its dividend could almost double over the next four years.
Lilly’s health care moat widens
The dividend raises don’t happen in a vacuum and are backed by one of the most explosive growth stories in the pharmaceutical sector.
In its first-quarter 2026 earnings call, Eli Lilly CEO Dave Ricks reported that revenue grew 56% compared to the same period in 2025, driven primarily by obesity and diabetes drugs Zepbound and Mounjaro, which together generated$12.8 billion in combined global revenue in Q1.
- The company also raised its full-year 2026 revenue guidance to between $82 billion and $85 billion.
- Moreover, Lilly launched Foundayo in April, a first-of-its-kind oral GLP-1 drug approved for weight management.
- Over 20,000 patients had already tried it within the first few weeks of launch, with 80% of those prescriptions going to patients who had never tried a GLP-1 therapy before.
“During the quarter, we delivered robust revenue growth, advanced our pipeline across all 4 therapeutic areas, announced multiple business development transactions, and invested to drive our future growth,” Ricks stated.
The growth story for LLY stock is far from over, given that Wall Street estimates the top-line to expand from $65 billion in 2025 to $133 billion in 2030.
Wall Street remains bullish on LLY stock
The 22 analysts covering Eli Lilly stock have a consensus rating of “strong buy” and an average price target of $1,263 — implying more than 27% upside from current levels.
One of the more bullish forecasts comes from Barclays, which recently raised its LLY stock price target to $1,400.
More on dividend stocks:
- Large-cap bank stock pays Warren Buffett $23M in annual dividends
- Early VIG ETF investors now earn a 6.6% yield on cost
- Costco quietly bumps its quarterly dividend by 13%
According to estimates, Zepbound and Foundayo could generate about $31 billion in combined U.S. sales next year, The Motley Fool notes, potentially rising to $45 billion by 2030.
That kind of top-line trajectory, if it materializes, makes future dividend growth look very achievable.
Eli Lilly has maintained an average dividend growth rate of about 15% over the past three and five years, and has raised its dividend for 12 consecutive years.
If Lilly keeps growing its payout at even a fraction of that pace, early investors in this dividend stock could find their yield-on-cost climbing even higher in the years ahead.
That’s the simple, powerful case for owning a great company and never selling.
